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Abstract
Background. It remains unknown how the COVID-19 pandemic has changed neuro-oncology clinical practice,
training, and research efforts.
Methods. We performed an international survey of practitioners, scientists, and trainees from 21 neuro-oncology
organizations across 6 continents, April 24–May 17, 2020. We assessed clinical practice and research environments,
institutional preparedness and support, and perceived impact on patients.
Results. Of 582 respondents, 258 (45%) were US-based and 314 (55%) international. Ninety-four percent of participants reported changes in their clinical practice. Ninety-five percent of respondents converted at least some
practice to telemedicine. Ten percent of practitioners felt the need to see patients in person, specifically because
of billing concerns and pressure from their institutions. Sixty-seven percent of practitioners suspended enrollment for at least one clinical trial, including 62% suspending phase III trial enrollments. More than 50% believed
neuro-oncology patients were at increased risk for COVID-19. Seventy-one percent of clinicians feared for their
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Key Points
• Clinical trial suspension, including phase III trials, was a hallmark of the pandemic.
• Practitioners and researchers perceive significant personal risk in doing their jobs.
• No consensus exists about risks for SARS-CoV-2 infection in neuro-oncology
patients.

Importance of the Study
This is the first international study of the impact of the COVID-19 pandemic on the field of
neuro-oncology. We observed changes in treatment options for patients with brain and spine
tumors, as well as burdens on clinicians and
researchers. We highlight major challenges
in the field, including suspension of clinical
trials, financial pressures for practitioners to

The COVID-19 pandemic has created many challenges for
healthcare.1 Neuro-oncology, which focuses on treating patients with primary and metastatic brain and central nervous
system (CNS) tumors and neurologic complications of
cancer, has faced challenges, particularly in maintaining
quality patient care and conducting clinical trials and laboratory research.
The provider pool in neuro-oncology is relatively small.
In 2018, there were 2600 members in the Society for
Neuro-Oncology (SNO) database, of which 1040 (40%)
were clinical members, including physicians, nurses,
and nurse practitioners. Equally small numbers of neurooncologists practice in Europe, Asia, and the rest of the
developed world. In the United States, approximately 25
000 malignant primary brain tumors are diagnosed annually.2 There are significant differences in incidence by world
region, with the highest incidence of malignant brain tumors in Northern Europe and Canada and the lowest in
Southeast Asia.
Gliomas are the most aggressive primary brain tumor,
and they make up the majority of diagnoses in neurooncology. Standard treatment for high-grade gliomas
includes surgical resection, followed by radiation and

see patients in person, and unmet safety concerns and high anxiety of practitioners and scientists. We also identified positive outcomes
in perceived quality of communication with
colleagues, patients and families, and reduced
travel and expenses for patients. This work
serves as a benchmark assessment of the field
during the early days of the pandemic.

temozolomide, an alkylating chemotherapy, and more recently, adjuvant use of tumor-treating fields. Often during
the course of care, patients receive dexamethasone, which
reduces edema; bevacizumab, a monoclonal antibody that
reduces angiogenesis and edema; and/or lomustine, an
alkylating chemotherapy. Radiation, temozolomide, and
lomustine all commonly cause myelosuppression and
lymphopenia.3,4 Immunotherapy is not approved for primary brain tumors; it remains under investigation and is
sometimes used as an off-label treatment at the time of
tumor recurrence.
The pandemic has required re-organization of clinic
visits, treatment and diagnostic testing schedules, and the
development of new processes managing therapy-related
complications.5 Patient management guidelines6–8 have
emerged, and discussions have centered on how to approach brain tumor patient treatment in resource-limited
settings and when significant exposure risk to patients
and health care providers exists.9 These recommendations
notwithstanding, it remains unknown as to what practically changed during the pandemic. The pandemic has
also affected medical teams. While physicians and allied
professionals are accustomed to dealing with stress and
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own personal safety or that of their families, specifically because of their clinical duties; 20% had inadequate
personal protective equipment. While 69% reported increased stress, 44% received no psychosocial support
from their institutions. Thirty-seven percent had salary reductions and 63% of researchers temporarily closed
their laboratories. However, the pandemic created positive changes in perceived patient satisfaction, communication quality, and technology use to deliver care and mediate interactions with other practitioners.
Conclusions. The pandemic has changed treatment schedules and limited investigational treatment options.
Institutional lack of support created clinician and researcher anxiety. Communication with patients was satisfactory. We make recommendations to guide clinical and scientific infrastructure moving forward and address the personal challenges of providers and researchers.
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The survey (Supplementary File 1) was developed
by the SNO COVID-19 task force, composed of adult
and pediatric oncologists, surgeons, radiation oncologists, laboratory scientists, and patient advocates.
The task force generated a set of general questions for
all the participants and in addition, we created several
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A total of 582 responses were received. Respondents
were located in the United States (258, 45%) and internationally (324, 55%; Figure 1). Of international respondents,
Europe (124/582, 21.3%) and Asia (91/582, 15.6%) were
the most represented regions, and within these, Spain
(37/582, 6.4%) and Japan (19/582, 3.3%) were the most
common countries of residence (Figure 1). Respondents
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Results

Methods

Figure 1.

pathways based on self-designation (eg, clinician [neurooncologist, neurosurgeon, or radiation oncologist], scientist, trainee [graduate students, postdocs, residents,
and fellows], social worker, training program director).
Participants who were members of more than one group
were asked to complete all applicable pathways. Topics
were selected based on the interests of the committee
and included questions about personal physical/mental
health, institutional response, clinical practice changes,
and individual career outcomes. Questions were a combination of binary response, multiple choice, Likert scale,
and free response. For some topics, respondents were
asked an overall question and then provided follow-up
binary questions for more detailed responses. The time
period for which questions were asked was since the
beginning of the COVID-19 pandemic in their respective
countries. The survey was available in English only. We
sent email survey invitations to members of 21 neurooncology organizations (Supplementary File 2) on 6
continents and advertised the survey on multiple social
media platforms. The survey was administered through
Survey Monkey (www.surveymonkey.com) from April
24 to May 17, 2020 and contained 134 questions, presented in a modular format with smart logic. We used R
4.0.0 software to generate summary statistics and perform statistical analyses. Categorical variables were
compared using chi-square tests, and continuous variables were compared using t-tests (when only 2 comparison groups) or ANOVA (when more than 2 comparison
groups). Data on sex, age, and ethnicity of the respondents were not collected for this survey.
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dying patients, the burden of these new challenges has
been unprecedented on professional and personal lives.
Clinicians need support during the COVID-19 pandemic,10
and guidelines exist for managing psychological stress
and maintaining healthy physical and mental states.11
However, we lack basic measurements of what clinicians
and researchers are experiencing.
Medical education was restructured so medical students, residents, and fellows may continue learning to
take care of patients and advance through their training
programs.12,13 Many programs are facing financial challenges that jeopardize the continuity of their training mission and the ability to accept new trainees.
Finally, scientists in neuro-oncology, attempting to understand the mechanisms underlying brain tumor development or identify new treatments, have had to stop or
postpone costly experiments and are now at risk of losing
funding to continue supporting these efforts
Here, we sought to address these issues and evaluate the perceived effects of these changes on neurooncology patient care. We asked the international
community of healthcare providers, scientists, and
trainees in the field to share their experiences during the
pandemic. This survey tool is not a method to identify the
root causes of the problems we identify. This framework
will guide further studies and recommendations on how
to best take care of CNS cancer patients, support clinical
caregivers, and identify opportunities for institutions to
continue to advance their research mission. These findings and principles will be broadly applicable to other
oncology specialties and those caring for patients with
chronic disease.
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Table 1.

Neuro-oncology Relevant Risk Factors for
COVID-19

Characteristics of Survey Respondents

Questions

N = 582

Do you primarily consider yourself a*: (%)
Clinician

227 (39.0%)

Clinician scientist

174 (29.9%)

Scientist

39 (6.7%)

None of the above

5 (0.9%)

No response

137 (23.5%)

Occupation (%)
Physician

311 (53.4%)

  Neuro-Oncologist (includes medical oncology, neurology, or pediatrics)

169 (29.0%)

  Neurosurgeon

94 (16.2%)

  Radiation Oncologist

48 (8.2%)

Scientist or researcher

46 (7.9%)

 dvanced practice practitioner (nurse practiA
tioner, physician assistant)

15 (2.6%)

 rainee (includes graduate students, postT
docs, residents, and fellows)

11 (1.9%)

Nurse

4 (0.7%)

Occupational, speech, or physical therapist

2 (0.3%)

Social worker

1 (0.2%)

Other

13 (2.2%)

No response

179 (30.8%)

Do you primarily treat adults or children? (%)
Adult patients

341 (58.6%)

Both adult and pediatric patients

85 (14.6%)

I do not provide direct care to patients

81 (13.9%)

Pediatric patients

54 (9.3%)

Neither

11 (1.9%)

No response

10 (1.7%)

Where do you primarily practice? (%)
 cademic center (main campus or its satelA
lite locations)

452 (77.7%)

Private practice

70 (12.0%)

Other

40 (6.9%)

No response

20 (3.4%)

World region (%)
United States

258 (44.3%)

Europe

124 (21.3%)

Asia

91 (15.6%)

Other

109 (18.7%)

*This question was required to move forward with the rest of the
survey (Supplementary File 1). If this was not answered, the respondent did not move past this question.

  

(341/582), 11.3% treated children (54/582), and 17.7%
treated both (85/582). Within the United States, most clinical practitioners were located at academic centers (79.0%
of non-researchers or 452), compared to private practice
(15.2% of non-researchers or 70).

Regarding beliefs of COVID-19 risk, 50.3% of respondents believed that neuro-oncology patients, before any
treatment, are at increased risk for contracting the virus
(180/487); 48.9% believed that steroids increase susceptibility to SARS-CoV-2 infection (173/487), but 43.8% reported
they were unsure and needed more evidence (155/487).
Twenty-eight percent believed that radiotherapy increases
infection risk (100/487). Forty-six percent believed that
temozolomide use increases susceptibility (165/487), and
21.6% believed that immunotherapy increases the risk
(77/487).

Effects on Clinical Practice and Patients
The pandemic required changes to clinical practice and
clinical trial opportunities, and in some cases, clinicians
reported pressures related to billing. While practitioners
voiced concerns about the emotional well-being of their
patients, there were perceived positive benefits to patients
in terms of communication of treatment plans and other
aspects of care.
Ninety-four percent of participants reported changes in
clinical practice due to the pandemic (361/386). The proportion reporting changes was highest in the United States
(96%, 169/177), compared to Europe (95%, 87/92) and Asia
(82%, 48/59, P = .003). Regarding survival, 44.5% thought
practice changes due to the pandemic would reduce survival, outside of any direct effect of SARS-CoV-2 infection
in their patients (151/339). This perception was highest in
Asia (54.0%, 30/53) compared to Europe (45.5%, 35/77) and
the United States (39.8%, 64/131), but not statistically significant (P = .101). Almost all respondents transitioned to
the use of video or telephone visits for some aspects of
clinical care (95.4%, 356/373; Figure 2). Use of telemedicine was slightly lower in Asia (85.2%, 48/56), compared
to Europe (97.7%, 86/88) and the United States (98.3%,
171/174, P = .001). A majority (56.8%, 192/338) reported
this transition was at least somewhat difficult; however,
80.1% received adequate information technology support
(285/351).
While practitioners greatly used telemedicine, 85.9%
(322/375) canceled what they deemed nonessential patient visits, and 16.2% moved patient visits at least
2 months into the future (61/376). Of these, 55% of scheduling changes were requested by patients or caregivers
(206/371). Regarding chemotherapy scheduling, 12.3%
(35/285) of practitioners moved inpatient chemotherapy by
up to 2 weeks and another 6.7% moved it out by up to a
month (19/285). Regarding referrals, 27.2% (101/372) practitioners referred patients to other institutions as a result
of pandemic pressures, and 65.4% (233/356) changed MRI
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representing those with direct patient contact included
53.4% physicians (311/582), 2.6% nurse practitioners and
physician assistants (15/582), 0.7% nurses (2/582), and
0.2% social workers (1/582); and 7.9% were researchers
(46/582; Table 1). Of the clinicians, 71.0% treated adults
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30%
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(55.9%)

50%

140
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(26.4%)

25%
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(12.6%)

Yes
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(17.3%)
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36
(11.8%)

D

100%

196
197
203
(54.3%) (54.6%) (56.2%)

50%

25%

Video

Proportion of visits switched by type

Percentage of respondents

Percentage of respondents

73
(20.9%)

Telephone

Switched visits to
telephone or video

75%

>75%

0%
No

C

50−74%

75%

17
(4.6%)

0%

26−49%

100%
Strongly disagree

Disagree

Neutral

Agree

Strongly agree

75%

25%

36
(49.3%)

36
(48.6%)

50%

16
(21.6%)

18
(24.3%)

4
(5.4%)

20
(27.4%)
6
(8.2%)

37
(50.0%)
23
(31.1%)

10
(13.7%)

1
(1.4%)

3
(4.1%)

11
(14.9%)

0%

0%
Patient Physician Instiution
or
caregiver

Travel burdens

Reason for changes

Cost of gas/food

Quality of care

Have these changes resulted in positive
patient outcomes in the following areas?

Figure 2. (A) Proportion of respondents reporting increased use of telephone and video visits; (B) percentage of cases transferred to video or
telephone; (C) primary person requesting change (respondents may have selected multiple options); and (D) proportion reporting positive patient
outcomes as a result of these changes.
  

schedules for their patients. Referrals to other providers
were most frequently reported in Asia (43.9, 25/57%), as
compared to Europe (17.0%, 15/88) or the United States
(24.4%, 42/172, P = .002).
Practitioners remained concerned about emotional
and palliative care of patients. Eighty percent of clinical
respondents noticed increased anxiety and depression
in their patients. Almost 20% of respondents noted an
increasing need for palliative care consults. Approximately
35% reported increased frequency in the discussion of endof-life issues since the beginning of the pandemic, but only
6.8% of end-of-life discussions were initiated by patients.
When asked whether there may be any positive aspects
of the pandemic, 88% agreed or strongly agreed (415/471)
that new technologies applied toward patient care were a
positive outcome. In fact, 84% (403/474) agreed or strongly
agreed that virtual meetings, including tumor boards, were
very helpful. Remarkably, 74.3% (347/ 467) of respondents
agreed or strongly agreed there was increased satisfaction of patients and families, due to decreased burdens of
spending time and money traveling to appointments. This
was highest in Asia (75%, 54/72), compared to Europe (67%,
69/103) and the United States (67.9%, 167/226, P = .0152).
About 59.5% (275/462) of practitioners also agreed or

strongly agreed that the quality of care exchange would be
positively affected by the change in norms during the pandemic. This was highest in Asia (63.4%, 45/71), compared
to the United States (62.2%) or Europe (50.0%, 50/100,
P = .0044).
In terms of reimbursement, 25.9% (83/321) of respondents stated they were not billing for technology-assisted
visits. This was highest in Asia (56.8%, 25/44) and Europe
(47.3%, 36/76), compared to the United States (6.9%, 11/160,
P < .001). Overall, 29.4% (94/320) of respondents had not
received effective support in billing for these types of visits.
Among those who reported billing for telephone and video
visits, 82.8% (193/233) reported receiving effective support
as compared to only 35.5% (27/76) of those who did not
bill for telephone and video visits (P < .001). Additionally,
nearly 10% (28/322) of respondents felt pressured by their
institution to do in-person visits, because of billing needs
and not because patient care necessitated an in-person
visit; this pressure was greatest in Asia (15.9%, 7/44), followed by the United States (7.9%, 11/156) and then Europe
(5.3%, 4/76, P = .104).
Notably, 67% of practitioners had suspended enrollment for any clinical trial (191/285), with 50% for phase
I trials (99/198), 52% for phase I/II trials (102/193), 53%
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(80.5%)

75%
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Performed surgery/patient
care without adequate PPE

Percentage of respondents

E

100%
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Figure 3. (A) Proportion of respondents reporting suspending clinical trials overall and by phase; (B) proportion of respondents reporting restrictions on performing elective surgeries; (C) outcome of elective surgical cases; (D) proportion reporting performing clinical care without appropriate
PPE; and (E) major factors guiding decision making for elective surgeries.
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oncologists had not changed their practice in any
significant way.
Twenty-eight percent of respondents believed that radiotherapy increases susceptibility to SARS-CoV-2 (100/363).
Radiation oncology plans for high-grade glioma were unchanged in 77.1% (37/48); 16.7% of cases were delayed by
2–4 weeks (8/48). For other indications, less than 40% of
radiation oncology plans remained unchanged (18/48);
approximately 58.3% (28/48) were delayed by at least 2
weeks. In cases of modified radiation plans, 68% (17/25)
were changed to shorter courses with higher daily doses
or shorter courses with a lower total dose (20%, 2/25;
Figure 4).

for phase II trials (106/197), and 62% for phase III trials
(124/202; Figure 3). The effect of COVID-19 on nontherapeutic trials was not measured by this survey, and
it is not possible to assess the effect on other human
subjects research. Regarding changes to treatment,
27.4% (46/168) of practitioners altered standard of care
regimens, and approximately 20% changed the timing
or dosing of infusions of bevacizumab (32/162). Fortythree percent (71/165) noted they were being more
careful using myelotoxic regimens because of unknowns
about SARS-CoV-2 infection and those at risk. Nine percent (14/156) of practitioners stopped off-label regimens
and 23.1% (36/156) reduced their frequency. Pediatric

Percentage of respondents
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Figure 4. (A) Overall proportion of respondents reporting salary reduction and proportion reporting reduction by region and (B) amount of salary
reduction.
  

In terms of changes in surgical practice, an average of
60% of elective cases were rescheduled into the future,
and remarkably, an average of 37% of elective procedures were canceled. About 14.3% (12/84) of cases that were
planned with an endonasal approach were converted to
craniotomy because of guidelines from respective institutions and surgical organizations. Notably, in cases where
there was inadequate personal protective equipment
(PPE), approximately 19.5% (16/82) of respondents reported already scheduled surgical procedures proceeding
at times or very often.

Effects on Laboratory Research
Neuro-oncology laboratory-based research significantly
slowed during the early months of the pandemic. Overall,
63% of respondents closed their laboratories (34/54), with
the number being 78.6% in the United States (22/28); 72.7%
of respondents stopped long-term experiments (32/44).

Respondents were not asked how long these laboratories were closed. Regarding funding prospects, 47.1%
(24/51) were “very concerned” about their own research
funding because of the economic strains associated with
the pandemic. For 34.9% (22/63), grant submission deadlines had been postponed, while 48.7% (19/39) believed
that pandemic-related changes gave them more time to
write scientific manuscripts. Nearly 30% of respondents
(17/57) reported their academic careers would be altered.
For the US-based respondents, only 13.3% (2/15) reported
that a visa status was at risk because of pandemic-related
pressures or policies; of note, the survey was conducted
prior to the June 22, 2020 presidential executive order suspending H1B and other foreign worker visas.

Work Hours, Salary, Benefits, and Job Security
While approximately 30% (125/433) of respondents reported increased work hours since the pandemic started,
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10% (27/298) of all respondents. While a majority faced
increased stress, only 56% (242/432) had psychosocial
support offered by their institution. Institutional psychosocial support availability varied significantly by
region, with 72% of US respondents (147/203) reporting
they were offered support, compared to 49.5% in Europe
(48/97) and 22.4% in Asia (15/67, P < .001).

Well-being

Discussion and Recommendations

The majority of respondents (75.7%, 206/272) reported
increased stress during the early months of the pandemic. This was higher in the United States (82%,
107/130), compared to Asia (61.2%, 34/52) and Europe
(58.8%, 34/52, P = .190). Regarding personal fears, 81.4%
(188/231) of practitioners had moderate or severe fear for
the health of their own families, specifically because of
their clinical duties; 71.4% (5/7) of researchers reported
that they were fearful for their health, specifically because of their research duties. Of all respondents, 53.8%
(161/299) had a moderate or severe concern about transmitting SARS-CoV-2 to their family, and 37.4% (111/297)
had moderate or severe concerns about transmitting to
other health care workers. “Severe concern” about one’s
own health and survival was reported in approximately

There have been several consensus statements and commentaries regarding neuro-oncology care during the pandemic,6,7,14 and analyses of the caregiver, not-for-profit
and brain tumor charity experiences.15,16 Our international
survey provides data that reveal the impact of the pandemic on the practice of neuro-oncology care, its effects
on clinical caregivers and patients, and research (Table 2).
First, the clinical practice dramatically changed in the first
several months of the pandemic. Transition to telemedicine
occurred almost universally, although it varied by region.
The closure of clinical trials, including phase III, was remarkable, especially given the poor standard of care options for patients with malignant gliomas. These closures
may reflect a lack of clinical research administrative support due to financial or safety concerns, a lack of flexibility

Approximately half of fellowship program directors worried about funding for their fellows because of the pandemic (20/38), and 40% (14/35) reported concerns they
would not be able to completely fill neuro-oncology fellowship slots for 2021.
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37% (160/436) had their salary temporarily reduced.
This was higher for respondents who primarily treated
adults (38%, 107/279) as compared to children (23%,
10/43, P = .0016). Of those with salary reductions, 53.6%
(74/138) had salaries reduced by at least 20%. Four percent (16/434) of respondents had been furloughed or
fired. The majority of respondents in Asia (58.2%, 39/67)
reported salary reduction, as compared to 33.2% US respondents (68/205) and 21.6% European respondents
(21/97, P < .001; Figure 5). Thirty-seven percent of clinical practitioners (85/228) and 57% of researchers (4/7)
reported a severe or moderate to severe fear of loss of
job security (P = .4291). This was higher in private practice (51.1%, 24/47) as compared to academic institutions (37%, 87/238) and was highest in the United States
(46.4%, 65/140), compared to Europe (34.5%, 20/58) or
Asia (37%, 20/55, P = .1303).

Percentage of respondents
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Key Findings and Recommendations for Institutions and COVID-19-Related Research Priorities for the Neuro-oncology Community

Key Findings
In some cases, telemedicine billing support for practitioners was inadequate.
Some practitioners felt pressure to do in-person visits.
Elective surgical practice changed.
Perception of increased anxiety in patients.
Respondents expressed concerns about their emotional well-being, safety for self and family, and financial impact from the pandemic.
Positive aspects of pandemic-based changes:
Technologies applied to patient care
Virtual meetings among colleagues
Perceived increase in patient satisfaction due to decreased time and money traveling to appointments
Major Recommendations
Institutions:
Modify and prioritize clinical trial infrastructure to ensure access for all patients.
Provide support for billing education for telephone and video visits.
Remove pressures on providers to see patients in-person when not clinically necessary.
Consider support for those with children and elder care responsibilities.
Provide means of psychological support to staff.
Areas of further research:
Effects of modified treatment schedules, in-person visit reductions, and surgical delays on patient outcomes.
 COVID-19 risk factors and outcomes in neuro-oncology patient population as a function of treatment; laboratory studies in disease
models.
Impact of financial changes on productivity and provider wellness.
Impact of financial changes on the conduct of basic science and clinical research.
Burdens as a function of provider and researcher gender and other demographics.

  
in government and pharmaceutical trial contracts, a
general lack of support by institutions themselves, the inability of institutions to safely promote social distancing,
difficulty obtaining operating room specimens, or other
causes. We also wonder whether this reflects a feeling
among providers that what we have to offer patients in
terms of treatment does not carry a significant chance of
benefit and therefore does not meet a threshold of risk to
participate. Comparing these findings to other cancers and
diseases will be helpful to identify the root cause of this
problem. A study of Canadian oncologists early in the pandemic similarly found that half of the respondents reported
a cessation of clinical trial accrual.17 Public pressure by patient advocacy groups, as well as more institutional experience with how to manage clinical trial complexities during
the crisis, may enable trials to remain open in the future.
It was remarkable that clinical practitioners believed that
patient satisfaction has increased because of improved
communication and travel reduction. This improved satisfaction may also be due to reduced delays in scheduling,
which we did not assess. There may be lessons here on
how to improve care beyond the pandemic and it will be
important to analyze patient and caregiver assessments to
corroborate this perception of the care team. For example,
respondents deemed virtual platforms beneficial for tumor
boards and communication with colleagues and this may
represent a lasting positive outcome of this pandemic. In

addition, such patient and caregiver-facing studies should
evaluate whether the usefulness of technology-assisted
visits is evident across the board, or if the elderly or patients in resource-poor settings who find it more difficult
to get access to care benefit the most. Lastly, these results
provide a platform for future outcomes research aimed at
assessing whether subsets of virtual care are inferior, noninferior, or superior than traditional health care delivery
in terms of medical outcomes, patient/caregiver satisfaction, resource utilization, and financial ramifications to the
health care system, families, and society. This may also be
an occasion to revisit the general usefulness of procedures
that were dropped during the pandemic.
Next, the degree of practitioners’ worries for their own,
and their families’ health because of potential exposures
they encounter at work is remarkable. It was striking that
15% of surgical procedures proceeded despite inadequate
PPE. Dogma is an early surgical intervention that is beneficial, particularly for patients with aggressive tumors. Many
of these procedures were delayed. The impact on survival
remains unknown.
A large percentage of respondents faced significant financial loss. Further work is required to determine the
long-term effects of these financial changes on productivity
and patient outcomes. We also note the significant pressures that exist for clinical practitioners and researchers
alike that come from the nature of the pandemic itself. For
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faced by Asian colleagues and patients reported elsewhere
is unprecedented.24 Our study did not address aspects of
discriminatory behavior as a result of the COVID-19 pandemic, nor were we able to assess the impact of stressors
faced by women providers and single parents responsible
for the care and education of their children.
Our work serves as a baseline appraisal of neurooncology during the early months of the pandemic.
Evidence suggests practitioners are at risk for burnout.
Clinical trial and off-label options are being reduced.
Standard treatment options are being modified. New research efforts have been slowed. On the other hand, our assessment provides institutions and advocacy groups with
a framework to intervene. As we all learn more, our hope
is that such interventions will make oncologic care more
efficient and improved on the other side of the pandemic.

Supplementary Material
Supplementary material is available at Neuro-Oncology
Advances online.
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example, institutions should take measures to support
those with children and elder caregiving responsibilities.
School closures or schools on altered schedules relying
on home education are likely disproportionately more
challenging for women. We did not assess this, but future
studies should identify the gender differentials in terms of
stress, productivity, and support received. Support may
come from tenure clock delays, financial support for those
with children, and technical help in the laboratory.
Additionally, the future of neuro-oncology research may
be in question, as trainees in the clinic and the laboratory
face challenges with funding and future training opportunities. While the economy as a whole is affected by the
pandemic, we wonder how much might be lost in terms
of advances in the field if trainees leave the pool of future
neuro-oncology practitioners and researchers.
We recommend hospitals and insurance providers offer
support for billing for video and telephone visits. Education
on Medicare (in the United States) and other insurance reimbursement policies for telemedicine use should be improved.
Ten percent of respondents felt pressured by their institution
to continue to see patients in person because of billing considerations. While there may be more nuanced reasons for
this that our survey did not capture, this compounds stress
without improving patient care, and clinical societies should
advocate toward the end of this practice. Beyond the perceived health risks of clinical practitioners and researchers,
the degree of reported professional caregiver anxiety and depression should be addressed by institutions.
While there are early observations that cancer patients in general may be more vulnerable to developing
COVID-19,18–23 this is not certain and there remain open
questions for further research, specifically in the care of
patients with brain tumors. There are strongly divergent
opinions on whether or not having a brain tumor increases the risk of contracting the virus and whether or
not temozolomide and standard steroid dosing affect susceptibility. Retrospective and laboratory-based studies
may yield insights. Additionally, comorbidities in the brain
tumor population, such as venous thrombosis and pulmonary embolism, or pulmonary disease in those with
Pneumocystis jirovecii, may have ramifications for the
susceptibility of this patient population to infection with
SARS-CoV-2.
A study of this kind is not without limitations given
the fluid nature of the pandemic and varied institutional,
national, and international responses. Due to the way that
the survey was advertised, it is not possible to calculate a
response rate. The number of total responses represents a
small proportion of membership in professional organizations that were contacted about participation, suggesting
that only a small proportion of the neuro-oncology community was captured by this survey.The survey was offered
only in English, which limited participation from nonEnglish speakers. These factors introduce the possibility of
selection bias. While we were able to capture the burden
providers felt related to the angst over uncertainty and
the well-being of their patients, staff, families, and themselves, we recognize that women and people of diverse
backgrounds may have been impacted in ways we did not
capture due to the lack of inclusion of these demographic
variables. The xenophobia that emerged resulting in bias
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